BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal
cells. This may be an effective treatment for hairy cell leukemia that has not responded to
treatment with cladribine.
PURPOSE: This phase II trial is studying BL22 immunotoxin to see how well it works in
treating patients previously treated with cladribine for hairy cell leukemia.